|
| Status |
Public on Jul 09, 2010 |
| Title |
NSPC DN2L condition cell line (expression analysis) |
| Sample type |
RNA |
| |
|
| Source name |
NSPC DN2L
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: NSPC DN2L
tissue: brain
|
| Growth protocol |
Cell lines were grown in DN2L conditions (DMEM-F12 supplemented with 20ng/ml epidermal growth (EGF; Invitrogen), 20ng/ml basic fibroblast growth factor (bFGF; Invitrogen), 1:50 B27 supplement (Invitrogen), 1:100 N2 supplement (Invitrogen), 10ng/ml leukemia inhibitory factor (LIF; Chemicon)
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNA was extracted from cultured primary cell lines using the Qiagen RNeasy Mini Kit after disruption with a Qiagen Tissue Lyser. RNA quality and quantity was assessed using a Agilent BioAnalyzer and a Nanodrop Spectrophotometer.
|
| Label |
biotin
|
| Label protocol |
Biotinylated cRNA were prepared with the Ambion MessageAmp kit for Illumina arrays
|
| |
|
| Hybridization protocol |
Standard Illumina hybridization protocol
|
| Scan protocol |
Standard Illumina scanning protocol
|
| Description |
RNA expression value
|
| Data processing |
The data were normalised using quantile normalisation with Partek Genomic Suites. Gene expression values from Illumina chips were generated by ANOVA (analysis of variance) to create a table of differentially expressed genes (as compared to the NSPCs), then exported to Ingenuity’s Pathway Analysis (IPA) platform for functional network and pathway analysis (Ingenuity® Systems, Redwood, CA, USA).
|
| |
|
| Submission date |
Jul 08, 2010 |
| Last update date |
Jul 08, 2010 |
| Contact name |
Huidong Shi |
| E-mail(s) |
hshi@augusta.edu
|
| Phone |
706-721-6000
|
| Organization name |
Augusta University
|
| Department |
Georgia Cancer Center
|
| Lab |
2125 K
|
| Street address |
1120 15th Street, CN2138
|
| City |
Augusta |
| State/province |
GA |
| ZIP/Postal code |
30912 |
| Country |
USA |
| |
|
| Platform ID |
GPL6947 |
| Series (1) |
| GSE22577 |
Meningioma initiating cells (MICs) derived from primary tumors |
|
